Efficacy and safety of formoterol delivered through the Novolizer®, a novel dry powder inhaler (DPI) compared with a standard DPI in patients with moderate to severe asthma

Pulmonary Pharmacology and Therapeutics

Volumn 21, Issue 1, 2008, Pages 47-53

  Otto Knapp, R ^a   Conrad, F ^b   Hosch S ^b   Metzenauer, P ^b   Maus, J ^c   Noga, O ^a   Petzold, U ^c   Kunkel, G ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

^b Fujisawa GmbH   (Germany)

^c MEDA Pharma   (Germany)

Author keywords

Aerolizer ; Asthma; Formoterol; Novolizer ; Powder inhaler

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CROMOGLYCATE DISODIUM; FORMOTEROL; FORMOTEROL FUMARATE; NEDOCROMIL; PLACEBO; SALBUTAMOL;

ADOLESCENT; ADULT; AGED; ARTICLE; ASTHMA; BRONCHOSPASM; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DEVICE; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRY POWDER; FEMALE; FLU LIKE SYNDROME; FORCED EXPIRATORY VOLUME; HUMAN; HYPERGLYCEMIA; MALE; METERED DOSE INHALER; MULTICENTER STUDY; POWDER INHALER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SIDE EFFECT; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION;

ADOLESCENT; ADULT; AGED; ASTHMA; BRONCHODILATOR AGENTS; CHILD; DOUBLE-BLIND METHOD; ETHANOLAMINES; FEMALE; HUMANS; MALE; MIDDLE AGED; NEBULIZERS AND VAPORIZERS; RESPIRATORY FUNCTION TESTS;

EID: 38049091375     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2006.11.003     Document Type: Article

References (19)

1. Bousquet J. Global initiative for asthma (GINA) and its objectives. Clin Exp Allergy 30 Suppl 1 (2000) 2-5
2. Fabbri L.M., and Hurd S.S. Global strategy for the diagnosis, management and prevention of COPD: 2003 update. Eur Respir J 22 (2003) 1-2
3. Tashkin D.P., and Cooper C.B. The role of long-acting bronchodilators in the management of stable COPD. Chest 125 (2004) 249-259
4. Andersson F., Stahl E., Barnes P.J., et al. Adding formoterol to budesonide in moderate asthma-health economic results from the FACET study. Respir Med 95 (2001) 505-512
5. Pauwels R.A., Lofdahl C.G., Postma D.S., et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 337 (1997) 1405-1411
6. Li X., Ward C., Thien F., Bish R., Bamford T., Bao X., et al. An antiinflammatory effect of salmeterol, a long-acting beta(2) agonist, assessed in airway biopsies and bronchoalveolar lavage in asthma. Am J Respir Crit Care Med 160 (1999) 1493-1499
7. ® dry powder inhaler in patients with persistent asthma. Respiration 71 (2004) 126-133
8. Wenzel S.E., Lumry W., Manning M., Kalberg C., Cox F., et al. Efficacy, safety, and effects on quality of life of salmeterol versus albuterol in patients with mild to moderate persistent asthma. Ann Allergy Asthma Immunol 80 (1998) 463-470
9. Juniper E.F., Svensson K., O'Byrne P.M., Barnes P.J., Bauer C.A., Lofdahl C.G., et al. Asthma quality of life during 1 year of treatment with budesonide with or without formoterol. Eur Respir J 14 (1999) 1038-1043
10. Miravitlles M., Murio C., Guerrero T., and Gisbert R. Costs of chronic bronchitis and COPD: a 1-year follow-up study. Chest 123 (2003) 784-791
11. Antonicelli L., Bucca C., Neri M., De Benedetto F., Sabbatani P., Bonifazi F., et al. Asthma severity and medical resource utilisation. Eur Respir J 23 (2004) 723-729
12. Fyrnys B., Stang N., and Wolf-Heuss E. Stability and Performance characteristics of a Budesonide Powder for Inhalation with a Novel Dry Powder Inhaler Device. Curr Opinion in Pulm Med Suppl 1 (2001) S7-S11
13. Von Berg A., Groß I., Leupold W., Engel M., Nguyen D.T., Ellers-Lenz B., et al. Asthmatic children generate significantly different peak inspiratory flow (PIF) through two different dry powder inhalers. Eur Respir J 22 Suppl 45 (2003) 494
14. Richter K., Ellers-Lenz B., Nguyen D.T., Munzel U., Maus J., and Magnussen H. Severe asthmatic patients generate significantly different peak inspiratory flows through two different dry powder inhalers. Eur Respir J 24 Suppl 48 (2004) 308
15. Richter K., Ellers-Lenz B., Nguyen D.T., Munzel U., Maus J., and Magnussen H. COPD patients generate significantly different peak inspiratory flows through two different dry powder inhalers. Eur Respir J 24 Suppl 48 (2004) 88
16. Newman S.P., Pitcairn G.R., Hirst P.H., Bacon R.E., O'Keefe E., Reiners M., et al. Scintigraphic comparison of budesonide deposition from two dry powder inhalers. Eur Respir J 16 (2000) 178-183
17. Munzel U., Marschall K., Fyrnys B., and Wedel M. Variability of fine particle dose and lung deposition of budesonide delivered through two multidose dry powder inhalers. Curr Med Res Opin 21 (2005) 827-833
18. Chuchalin A.G., Kremer H.J., Metzenauer P., O'Keefe E., and Hermann R. Clinical equivalence trial on budesonide delivered either by the Novolizer multidose dry powder inhaler or the Turbuhaler in asthmatic patients. Respiration 69 (2002) 502-508
19. Magnussen H., Richter K., von Berg A., Nguyen T.D., Petzold U., Munzel U., et al. Significantly different peak inspiratory flows (PIF) through two different dry powder inhalers (DPI) in critical patient groups. Eur Respir J 26 Suppl 49 (2005) 339 [poster 2220]